Logo

Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

Share this

Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

Shots:

  • The P-II POC study assess safety and efficacy of ANG-3777 (2.0 mg/kg- IV) + SOC vs PBO + SOC in ~100 patients in a ratio (1:1) hospitalized with confirmed COVID-19 pneumonia with 1EPs as the proportion of patients alive- without the need for mechanical ventilation and renal replacement therapy (on an ongoing basis) @28day
  • Following the success of the P-II study- the company plans to submit an IND for the therapy in the US. Additionally- Angion is conducting a P-III study of ANG-3777 to improve kidney function and reduce the severity of transplant-associated AKI in patients showing evidence of early kidney dysfunction and in a P-II clinical trial for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass
  • ANG-3777 is designed to mimic the biological activity of hepatocyte growth factor (HGF)- which activates the c-Met cascade of pathways involved in tissue repair and organ repair

Click here to read full press release/ article | Ref: PRNewswire | Image: Angion


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions